Launch of Phase 3 clinical trial with NefeconNefecon in Japan
2024-07-04
STOCKHOLM, July 4, 2024 /PRNewswire/ --
Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX)
("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy (IgAN).
The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in Japan, with an estimated 33,000 patients in Japan* assumed to be suffering from this disease and with limited treatment options for IgAN patients in this country.
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan - Calliditas Therapeutics AB
*Japan Intractable Disease Information Center
CONTACT:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: [email protected]
The information was sent for publication, through the agency of the contact persons set out above, on July 4, 2024 at 08:30 a.m. CET.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/launch-of-phase-3-clinical-trial-with-nefecon-in-japan,c4011121
The following files are available for download:
SOURCE Calliditas Therapeutics
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。